Mayne Pharma Group Limited (MAYNF)
USD 4.25
(3.41%)
USD 4.25
(3.41%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -2.05 AUD | 46.75% |
| 2023 | -3.85 AUD | -20.31% |
| 2022 | -3.20 AUD | -20.75% |
| 2021 | -2.65 AUD | -119.01% |
| 2020 | -1.21 AUD | 68.24% |
| 2019 | -3.81 AUD | -108.2% |
| 2018 | -1.83 AUD | -247.58% |
| 2017 | 1.24 AUD | 30.53% |
| 2016 | 0.95 AUD | 331.82% |
| 2015 | 0.22 AUD | -68.12% |
| 2014 | 0.69 AUD | 630.77% |
| 2013 | -0.13 AUD | -122.41% |
| 2012 | 0.58 AUD | 262.5% |
| 2011 | 0.16 AUD | -57.89% |
| 2010 | 0.38 AUD | 153.52% |
| 2009 | -0.71 AUD | -9.23% |
| 2008 | -0.65 AUD | -10.17% |
| 2007 | -0.59 AUD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.44 AUD | 78.64% |
| 2024 Q3 | -0.62 AUD | 28.74% |
| 2024 Q4 | -0.62 AUD | 4.84% |
| 2024 FY | - AUD | 43.12% |
| 2024 Q2 | -0.87 AUD | -97.73% |
| 2023 FY | - AUD | -20.31% |
| 2023 Q3 | -1.15 AUD | 29.88% |
| 2023 Q1 | -0.69 AUD | 71.37% |
| 2023 Q2 | -1.64 AUD | -137.68% |
| 2023 Q4 | -2.06 AUD | -79.13% |
| 2022 Q3 | -0.86 AUD | -38.71% |
| 2022 Q2 | -0.62 AUD | -51.22% |
| 2022 FY | - AUD | -20.75% |
| 2022 Q1 | -0.41 AUD | -32.26% |
| 2022 Q4 | -2.41 AUD | -180.23% |
| 2021 Q3 | -0.17 AUD | 92.67% |
| 2021 Q4 | -0.31 AUD | -82.35% |
| 2021 Q1 | -1.16 AUD | -28.89% |
| 2021 FY | - AUD | -119.01% |
| 2021 Q2 | -2.32 AUD | -100.0% |
| 2020 Q4 | -0.90 AUD | -87.5% |
| 2020 FY | - AUD | 68.24% |
| 2020 Q1 | -0.12 AUD | 96.5% |
| 2020 Q2 | -0.23 AUD | -91.67% |
| 2020 Q3 | -0.48 AUD | -108.7% |
| 2019 Q1 | 0.02 AUD | -92.86% |
| 2019 FY | - AUD | -108.2% |
| 2019 Q4 | -3.43 AUD | -100.58% |
| 2019 Q3 | -1.71 AUD | -8650.0% |
| 2019 Q2 | 0.02 AUD | 0.0% |
| 2018 Q3 | 0.28 AUD | 123.53% |
| 2018 Q1 | -1.19 AUD | -1181.82% |
| 2018 FY | - AUD | -247.58% |
| 2018 Q4 | 0.28 AUD | 0.0% |
| 2018 Q2 | -1.19 AUD | 0.0% |
| 2017 Q1 | 0.50 AUD | 127.27% |
| 2017 FY | - AUD | 30.53% |
| 2017 Q2 | 0.52 AUD | 4.0% |
| 2017 Q3 | 0.11 AUD | -78.85% |
| 2017 Q4 | 0.11 AUD | 0.0% |
| 2016 Q4 | 0.22 AUD | 0.0% |
| 2016 Q3 | 0.22 AUD | -8.33% |
| 2016 Q2 | 0.24 AUD | 0.0% |
| 2016 Q1 | 0.24 AUD | 374.31% |
| 2016 FY | - AUD | 331.82% |
| 2015 Q3 | 0.05 AUD | -23.33% |
| 2015 Q2 | 0.07 AUD | 0.0% |
| 2015 Q4 | 0.05 AUD | 0.0% |
| 2015 FY | - AUD | -68.12% |
| 2015 Q1 | 0.07 AUD | -68.57% |
| 2014 Q4 | 0.21 AUD | 0.0% |
| 2014 Q2 | 0.15 AUD | 0.0% |
| 2014 Q3 | 0.21 AUD | 40.0% |
| 2014 FY | - AUD | 630.77% |
| 2014 Q1 | 0.15 AUD | 2930.19% |
| 2013 Q4 | -0.01 AUD | 0.0% |
| 2013 Q3 | -0.01 AUD | 0.0% |
| 2013 FY | - AUD | -122.41% |
| 2012 FY | - AUD | 262.5% |
| 2011 FY | - AUD | -57.89% |
| 2010 FY | - AUD | 153.52% |
| 2009 FY | - AUD | -9.23% |
| 2008 FY | - AUD | -10.17% |
| 2007 FY | - AUD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AstraZeneca PLC | 3.84 USD | 153.385% |
| Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | 152.835% |
| CSPC Pharmaceutical Group Limited | 0.07 USD | 3028.571% |
| Clarus Therapeutics Holdings, Inc. | -8.04 USD | 74.502% |
| Novartis AG | 7.63 USD | 126.868% |
| PT Kalbe Farma Tbk. | 0.00 USD | 52664.103% |